Suppr超能文献

噻吩并吡啶类药物或阿司匹林用于预防血管疾病高危患者的中风及其他严重血管事件?对随机试验证据的系统评价

Thienopyridines or aspirin to prevent stroke and other serious vascular events in patients at high risk of vascular disease? A systematic review of the evidence from randomized trials.

作者信息

Hankey G J, Sudlow C L, Dunbabin D W

机构信息

Department of Medicine, University of Western Australia, Perth, Australia.

出版信息

Stroke. 2000 Jul;31(7):1779-84. doi: 10.1161/01.str.31.7.1779.

Abstract

BACKGROUND AND PURPOSE

Aspirin is the most widely studied and prescribed antiplatelet drug for patients at high risk of vascular disease. We aimed to establish how the thienopyridines (ticlopidine and clopidogrel) compare with aspirin in terms of effectiveness and safety.

METHODS

We did a systematic review of all unconfounded randomized trials comparing either ticlopidine or clopidogrel with aspirin for patients at high risk of vascular disease. The primary outcome was vascular events (stroke, myocardial infarction, or vascular death). Adverse outcomes were intracranial and extracranial hemorrhage, upper and lower gastrointestinal disturbances, neutropenia, thrombocytopenia, and skin rash.

RESULTS

In 4 trials among 22 656 patients (including 9840 presenting with a transient ischemic attack/ischemic stroke), the thienopyridines reduced the odds of a vascular event by 9% (odds ratio 0.91, 95% CI 0.84 to 0. 98; 2P=0.01), preventing 11 (95% CI 2 to 19) events per 1000 patients treated for approximately 2 years. The thienopyridines produced significantly less gastrointestinal hemorrhage and upper gastrointestinal upset (indigestion/nausea/vomiting) than did aspirin. Both thienopyridines increased the odds of skin rash and of diarrhea (ticlopidine by approximately 2-fold and clopidogrel by approximately one third). Only ticlopidine increased the odds of neutropenia.

CONCLUSIONS

The thienopyridines appear modestly more effective than aspirin in preventing serious vascular events in high-risk patients. Clopidogrel appears to be safer than ticlopidine and as safe as aspirin, making it an appropriate, but more expensive, alternative antiplatelet drug for patients unable to tolerate aspirin. However, there is insufficient information to determine which particular types of patients would benefit most, and which least, from clopidogrel instead of aspirin.

摘要

背景与目的

阿司匹林是针对血管疾病高危患者研究和应用最为广泛的抗血小板药物。我们旨在确定噻吩并吡啶类药物(噻氯匹定和氯吡格雷)在有效性和安全性方面与阿司匹林相比情况如何。

方法

我们对所有比较噻氯匹定或氯吡格雷与阿司匹林用于血管疾病高危患者的无混杂因素的随机试验进行了系统评价。主要转归为血管事件(卒中、心肌梗死或血管性死亡)。不良转归为颅内和颅外出血、上消化道和下消化道紊乱、中性粒细胞减少、血小板减少及皮疹。

结果

在22656例患者中的4项试验(包括9840例短暂性脑缺血发作/缺血性卒中患者)中,噻吩并吡啶类药物使血管事件的几率降低了9%(比值比0.91,95%可信区间0.84至0.98;P=0.01),每1000例接受约2年治疗的患者可预防11例(95%可信区间2至19例)事件。噻吩并吡啶类药物引起的胃肠道出血和上消化道不适(消化不良/恶心/呕吐)明显少于阿司匹林。两种噻吩并吡啶类药物均增加了皮疹和腹泻的几率(噻氯匹定约增加2倍,氯吡格雷约增加三分之一)。仅噻氯匹定增加了中性粒细胞减少的几率。

结论

在预防高危患者严重血管事件方面,噻吩并吡啶类药物似乎比阿司匹林略有效。氯吡格雷似乎比噻氯匹定更安全,且与阿司匹林一样安全,使其成为不能耐受阿司匹林患者的一种合适但更昂贵的替代抗血小板药物。然而,尚无足够信息确定哪些特定类型的患者使用氯吡格雷而非阿司匹林获益最大,哪些获益最小。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验